Global Respiratory Disease Vaccine Market Projected to Grow at 2.6% CAGR, Reaching $77.48 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Respiratory Disease Vaccine Industry Market Size Be by 2025?
The market size for vaccines targeting respiratory diseases has seen a slight increase in the past few years. The market value is predicted to rise from $69.99 billion in 2024 to $70.03 billion in 2025, showcasing a compound annual growth rate (CAGR) of 0.1%. The growth observed in the historical period can be linked to a higher incidence of respiratory diseases, heightened awareness about vaccination in the public, initiatives promoting public health, and an increasing demand for efficient and easier-to-tolerate vaccines.

What's the Long-Term Growth Forecast for the Respiratory Disease Vaccine Market Size Through 2029?
In the coming years, the market for respiratory disease vaccines is predicted to experience consistent growth. The market is estimated to increase to $77.48 billion by 2029, with a compound annual growth rate (CAGR) of 2.6%. The expansion during the forecast period can be linked to factors such as the aging demographic, increased healthcare expenditures, investments in vaccines, and readiness for potential pandemics. The period is anticipated to see major trends like innovative vaccine creations, cooperative studies, advancements in the sphere of vaccine evolution, and medication approvals.

View the full report here:
https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

What Are the Key Growth Drivers Fueling the Respiratory Disease Vaccine Market Expansion?
The rise in tuberculosis incidents is set to spur the expansion of the respiratory disease vaccine market. Caused by the bacterium Mycobacterium tuberculosis, tuberculosis (TB) is a kind of respiratory illness that mainly affects the lungs and can potentially affect other body organs and systems, resulting in diverse complications. The escalating TB prevalence could potentially encourage the creation and distribution of vaccines for respiratory diseases to mitigate the propagation of TB. For instance, The Centers for Disease Control and Prevention, a US government agency, reported in November 2023 that there were 8,331 tuberculosis cases in the United States in 2022, indicating a 5.9% increase from 2021. With a 5.5% increase from the previous year, the incidence rate surged to 2.5 cases per 100,000 people. Consequently, the growing prevalence of tuberculosis is expected to stimulate the respiratory disease vaccine market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

What Long-Term Trends Will Define the Future of the Respiratory Disease Vaccine Market?
Major firms in the respiratory disease vaccine market are focusing their efforts on developing innovative products to elevate their effectiveness and deliver enhanced solutions for the prevention and treatment of respiratory disease infections. Take for example, Pfizer Inc., an American pharmaceutical firm, which in May 2023, gained the approval of the Food and Drug Administration (FDA) for ABRYSVO (Respiratory Syncytial Virus Vaccine), a vaccine designed to prevent lower respiratory tract disease induced by the respiratory syncytial virus in individuals who are 60 years and above. ABRYSVO, a vaccine without adjuvant, consists of a duo of preF proteins customized to optimize immunity against RSV A and B strains and its safety and efficiency have been clinically validated.

How Is the Respiratory Disease Vaccine Market Segmented?
The respiratory disease vaccine market covered in this report is segmented -

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine
2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections
3) By Age: Infant, Adolescent, Adult
4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:
1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine
2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine
3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12924&type=smp

Which Companies Are Leading the Charge in Respiratory Disease Vaccine Market Innovation?
Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

Which Regions Are Leading the Global Respiratory Disease Vaccine Market in Revenue?
Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12924

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.